ライフサイエンスコーパス: desferrioxamine

1 ponsive to intracellular iron chelation with desferrioxamine.

2 ontrols who were on long-term treatment with desferrioxamine.

3 by hypoxia and the hypoxia mimics cobalt and desferrioxamine.

4 either cobalt chloride or the iron chelator desferrioxamine.

5 d are either hypoxic or have been exposed to desferrioxamine.

6 henylphenylenediamine, and the iron chelator desferrioxamine.

7 hich is also inducible by the iron chelator, desferrioxamine.

8 ere also induced by exposure of the cells to desferrioxamine.

9 f the inducible response to both hypoxia and desferrioxamine.

10 factor beta (TGF-beta) and the hypoxia mimic desferrioxamine.

11 Lysosomal iron chelation was achieved with desferrioxamine.

12 cally decreased RAGE induction by hypoxia or desferrioxamine.

13 tection was not observed with iron-saturated desferrioxamine.

14 ructurally unrelated chelators dipyridyl and desferrioxamine.

15 The iron chelator desferrioxamine (100 microM) in vitro prevented the amin

16 (30 and 100 U ml-1), or by the iron chelator desferrioxamine (100 microM).

17 l body radiation exposure relative to (89)Zr-desferrioxamine-5B1.

18 rotocol involved treatment of the cells with desferrioxamine, a cell-permeant, Fe(III)-specific chela

19 f intracellular iron-dependent peroxidation, desferrioxamine, abolished the elevation in cellular ROS

20 Chelation of iron by desferrioxamine abrogates the antiparasitic activity of

21 rioxamine: like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1alpha

22 Moreover, cobalt chloride and desferrioxamine activated HIF-1 but not IAP-2.

23 Pretreatment of astrocytes with desferrioxamine also did not induce the inhibition of T.

24 Co2+ and desferrioxamine also increased VEGF levels, while inhibi

25 n, treatment of cells with the iron chelator desferrioxamine also reduced MLH1 and PMS2 levels, in ke

26 Desferrioxamine, an avid iron chelator, had no effect on

27 plates that are homogenized and treated with desferrioxamine, an Fe(III) chelator, prior to packing t

28 a-3 PUFA, cotreatment with the iron chelator desferrioxamine, an inhibitor of iron-dependent lipid pe

29 MEL cells, expression of TfR1 was induced by desferrioxamine, an iron chelator, and it was reduced by

30 o inhibited significantly in the presence of desferrioxamine, an iron chelator, but this protection w

31 mparable to synthetic metal chelating agents desferrioxamine and clioquinol.

32 The iron chelators desferrioxamine and cobalt chloride, which induce hypoxi

33 generation correlated positively with use of desferrioxamine and deferriprone respectively (two studi

34 B (FatB), PB (FpuA), schizokinen (YfiY), and desferrioxamine and ferrichrome (YxeB).

35 m/z signals for Th-hydroxamate siderophore (desferrioxamine and ferrichrome) complexes, with Th comp

36 Desferrioxamine and hypoxia were also able to suppress t

37 UTR is reduced after treatment of cells with desferrioxamine and increased after interleukin-1 stimul

38 alternatively labeled with (124)I- or (89)Zr-desferrioxamine and injected into mice bearing either ma

39 igands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a si

40 ence of transition metal chelators (DTPA +/- desferrioxamine), and was inhibited by catalase, superox

41 Iron chelators, such as EDTA, desferrioxamine, and deferiprone, were found to cause th

42 2C12 cells to dimethyl oxalylglycine (DMOG), desferrioxamine, and hypoxia, all inhibitors of prolyl h

43 Normoxic inducers of HIF (CoCl(2), desferrioxamine, and l-mimosine) and 100 ng/ml ANGPTL4 s

44 r doses, in combination with the older agent desferrioxamine, and recent trials' data have shown effi

45 The presence of the siderophore desferrioxamine B (a strong Mn(III)-complexing ligand) e

46 ises an iron-specific chelating biomolecule, desferrioxamine B (DFB), covalently immobilized on a mes

47 xperiments with the strong Mn(III) chelator, desferrioxamine B (DFB), in seawater indicated that the

48 preparation and in vivo evaluation of (89)Zr-desferrioxamine B (DFO)-7E11, a novel (89)Zr-labeled mon

49 t study, we report the preparation of (89)Zr-desferrioxamine B (DFO)-J591, a novel (89)Zr-labeled mon

50 eB binds ferrioxamine B (FO, Fe-siderophore)/desferrioxamine B (DFO, apo-siderophore) in vitro.

51 by examining the effects of the siderophore desferrioxamine B (DFOB) on Fe removal from aquatic humi

52 ted the potential synergism between ligands (desferrioxamine B (DFOB) or N,N'-Di(2-hydroxybenzyl)ethy

53 lization was found for all ligands examined (desferrioxamine B (DFOB), 2'-deoxymugineic acid (DMA), e

54 tic acid (NTA), iminodiacetic acid (IDA) and desferrioxamine B (DFOB), as well as with Suwannee River

55 The effect of citric acid (CA), desferrioxamine B (DFOB), fulvic acid (FA), and humic ac

56 he presence of a representative siderophore, desferrioxamine B (DFOB), iron (Fe) was released at high

57 Mn(III) stabilized by pyrophosphate (PP) and desferrioxamine B (DFOB).

58 ovel radiolabeled monoclonal antibody (89)Zr-desferrioxamine B [DFO]-J591 for immuno-PET of prostate-

59 We found that the ferric siderophores desferrioxamine B and aerobactin were not readily bioava

60 Conjugating the peptide to Desferal (desferrioxamine B mesylate), a chelator in therapeutic u

61 hich redox active iron had been removed with desferrioxamine B prevented all of the gpt- mutations ab

62 s complexed with deferoxamine (also known as desferrioxamine B, desferoxamine B), conjugated either t

63 three siderophores of the hydroxamate type: desferrioxamine B, desferrioxamine E, and coelichelin.

64 ), and natural iron binding compounds (e.g., desferrioxamine B, ferrichrome A).

65 ng alcaligin, enterobactin, ferrichrome, and desferrioxamine B.

66 ATF3 could also be induced by desferrioxamine but not by the mitochondrial poison cyan

67 assays was stimulated by Ni2+, hypoxia, and desferrioxamine, but this activation was not diminished

68 PASMCs, HIF-1alpha activation by CoCl(2) or desferrioxamine causes DRP1-mediated fission.

69 Most received desferrioxamine chelation.

70 imaging using (89)Zr-DFO-mAb-B43.13 (DFO is desferrioxamine) clearly delineated CA125-positive OVCAR

71 common in the deferiprone group than in the desferrioxamine controls (four [27%] vs 20 [67%], p=0.02

72 odds ratio for excess myocardial iron in the desferrioxamine controls versus the deferiprone group wa

73 70% [SD 6.5] vs 63% [6.9], p=0.004) than the desferrioxamine controls.

74 n chelating resin, or the chelators EDTA and desferrioxamine decreased monatin and indole loss for so

75 Exposure to the iron chelator desferrioxamine decreased SPH forming efficiency and the

76 sponse to the clinically applied medications desferrioxamine, deferiprone, and deferasirox.

77 dies indicated that some of the genes in the desferrioxamine (des) and coelichelin (cch) biosynthetic

78 (89)Zr-desferrioxamine (df)-onartuzumab was synthesized using a

79 Desferrioxamine (DFO) and the hydroxypiridinone (HPO) de

80 Desferrioxamine (DFO) and/or a NIRF dye (FL) were conjug

81 Desferrioxamine (DFO) is currently the preferred chelato

82 e hypoxia and the hypoxia mimetics CoCl2 and desferrioxamine (DFO) stabilize it.

83 An exendin-4 derivative conjugated to desferrioxamine (DFO) was used for radiolabeling with th

84 2 mRNA in K562 cells was not up-regulated by desferrioxamine (DFO), a cell membrane-permeable iron ch

85 monstrated with the classical iron chelator, desferrioxamine (DFO), and was not observed for the DFO-

86 Here, we reveal how the iron-binding ligands desferrioxamine (DFO), di-2-pyridylketone-4,4-dimethyl-3

87 Here, we evaluated [(89)Zr]Zr-desferrioxamine (DFO)-daratumumab PET/CT imaging in MM t

88 The stability and specificity of (89)Zr-desferrioxamine (DFO)-labeled CD30-specific AC-10 antibo

89 inhibitory properties compared with those of desferrioxamine (DFO).

90 n alternative to the gold standard chelator, desferrioxamine (DFO).

91 s (such as CoCl2) or iron chelators [such as desferrioxamine (DFO)].

92 laminochroman (2-MAC; 0.3 to 2.5 microM) and desferrioxamine (DFO; 0.25 to 2 mM) reduced cell damage

93 the IEF extract and a siderophore standard (desferrioxamine; DFO) suggested the presence of HS funct

94 amine (SNAP), a nitric oxide (NO) donor, and desferrioxamine (DFx) and cobalt chloride, mimics of cel

95 The iron chelator desferrioxamine (DFX) induces the activity of the human

96 HIF-1 inducers, cobalt chloride (CoCl2) and desferrioxamine (DFX), on HIF-1 expression and neuroprot

97 tional chelation treatment with subcutaneous desferrioxamine does not prevent excess cardiac iron dep

98 etase superfamily, catalyzes the key step in desferrioxamine E biosynthesis: ATP-dependent trimerisat

99 of the hydroxamate type: desferrioxamine B, desferrioxamine E, and coelichelin.

100 rescine (HSP) and is structurally related to desferrioxamine E, which is a macrocyclic trimer of N-hy

101 cells exposed to 1% O2, cobalt chloride, or desferrioxamine, each of which also increased levels of

102 e activity and doubling time, whereas Zn and desferrioxamine extended these recoveries and rescued Co

103 e selection of small molecule drugs, such as desferrioxamine (Fe chelator) and clioquinol (Fe, Cu, an

104 re site-specifically conjugated to maleimide-desferrioxamine for (89)Zr radiolabeling and subsequent

105 Treatment with the iron chelator desferrioxamine for 16 h prevented both translation and

106 mine for Th and a 5-fold lower affinity than desferrioxamine for Fe.

107 errichrome has a 5-fold higher affinity than desferrioxamine for Th and a 5-fold lower affinity than

108 e report the novel use of a metallo-complex, desferrioxamine-gallium (DFO-Ga) that targets P. aerugin

109 Cells that were not pretreated with desferrioxamine had Fe(III) EPR signals that were equall

110 eversed the increase in [Fe(2+)](i), whereas desferrioxamine had little effect.

111 The iron chelator desferrioxamine had no effect on DNA synthesis.

112 ssed mRNA lacked the iron-responsive element desferrioxamine had no effect upon localisation.

113 a phase I dose-escalation study with (89)Zr-desferrioxamine-IAB2M ((89)Zr-IAB2M), an anti-prostate-s

114 find that depletion of intracellular iron by desferrioxamine impairs SFT transport and iron-binding f

115 Although a controlled study of desferrioxamine in Alzheimer's disease(AD) had some prom

116 Oral deferiprone is more effective than desferrioxamine in removal of myocardial iron.

117 of >13%, which is much greater than that of desferrioxamine in this model.

118 Surprisingly, desferrioxamine increased the rate of LDL modification w

119 cells were pretreated with the iron chelator desferrioxamine, indicating a role for iron in inactivat

120 synthesis was inhibited by the iron chelator desferrioxamine, indicating that cytosolic DA and dihydr

121 Conversely, the classical iron chelator desferrioxamine induced autophagosome accumulation only

122 inepentaacetic acid and, to a lesser extent, desferrioxamine inhibited LDL oxidation when added durin

123 ee alpha-biliverdin yield in the presence of desferrioxamine is significantly increased in the "aged"

124 study, we describe the generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-mal

125 Here we describe the development of (89)Zr-desferrioxamine-labeled transferrin ((89)Zr-transferrin)

126 fective mammalian cells to the iron chelator desferrioxamine leads to degradation of ferritin in the

127 HeLa cells are exposed to the iron chelator desferrioxamine, levels of SFT mRNA increase in an actin

128 using cobalt chloride and the iron chelator desferrioxamine: like hypoxia, cobalt chloride and desfe

129 e (89)Zr-labeled mouse serum albumin ((89)Zr-desferrioxamine-mAlb) as a model radiotracer to assess u

130 tra- and intertumoral distribution of (89)Zr-desferrioxamine-mAlb.

131 s induced by iron can be inhibited by either desferrioxamine mesylate (an iron chelator) or succinyl

132 s shown to be independent of HIF-1alpha, and desferrioxamine mesylate (DFO) and cobalt chloride induc

133 Treatment of PC12 with the iron chelator, desferrioxamine mesylate (DFO, 50 microM for 24 h), sign

134 However, as shown earlier with IRP1, both desferrioxamine mesylate and succinyl acetone will inhib

135 uli: hypoxia (strong) > iron chelation, e.g. desferrioxamine (moderate) >> transition metals, e.g. co

136 introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients

137 methyl-1-pyrroline-1-oxide, the antioxidants desferrioxamine, nordihydroguaiaretic acid, and Amytal,

138 h intravenous infusion of the iron chelator desferrioxamine on the pulmonary circulation.

139 poB100 in primary hepatocytes was blocked by desferrioxamine or antioxidant cotreatment.

140 mbient or chemical hypoxia (upon exposure to desferrioxamine or cobalt chloride), an effect that requ

141 tes exceeded that obtained with deferiprone, desferrioxamine, or deferasirox at similar iron-binding

142 h the treatment of hypoxia, cobalt chloride, desferrioxamine, or dimethyloxalyglycine, regardless of

143 In primary human endothelial cells, hypoxia, desferrioxamine, or infection with Ad2/HIF-1alpha/VP16,

144 Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was

145 Desferrioxamine prevented mitochondrial ROS production a

146 e that a hydroxylase inhibitor, hypoxia, and desferrioxamine promote the functional and physical inte

147 The 'Desferrioxamine Protocol' examined the effects of an 8 h

148 In the Desferrioxamine Protocol, desferrioxamine significantly

149 cell lines incubated with the iron chelator desferrioxamine resulted in PC7 down-regulation.

150 In the Desferrioxamine Protocol, desferrioxamine significantly elevated both PASP (P < 0.

151 Recovery was partial following cessation of desferrioxamine six weeks later.

152 ligate iron and also by using the chelator, desferrioxamine, that forms a redox-inactive iron comple

153 -fold increase in the level of PfIRPa in the desferrioxamine-treated cultures versus control or iron-

154 und not to alter "free" iron levels, whereas desferrioxamine treatment significantly raised these lev

155 The protective effect of desferrioxamine was mediated by the prevention of lysoso

156 ity by a hydroxylase inhibitor, hypoxia, and desferrioxamine was severely blocked by the adenoviral o

157 so demonstrate responses to both hypoxia and desferrioxamine which are independent of HIF-1 beta and

158 Desferrioxamine, which stabilizes HIF1/2alpha, did not a